New Drug Generates Hope

A team comprised of scientists from several countries say that the new drug Copaxone is not only effective in treating symptoms of Multiple Sclerosis, but also has the potential to protect the brain and combat the MS disease over time.

Close to 250 patients were studied in both Canada and Europe through the use of magnetic resonance imaging (MRI) technology, and indications were that the drug reduced new brain lesions by some 35% over a nine month period. Further, Copaxone reduced the relapse rate by at least a third.

Dr. Luanne Metz, lead Canadian investigator in the study, was quoted in the National Post as stating that "without a doubt, measuring with MRI...Copaxone protects the brain. The thing that is more exciting really is that the benefits increase over time."

There are about 50,000 persons with MS in Canada alone, usually between the ages of 20 and 40. The disease results from the body's own immune system attacking nerve fibre insulation (myelin) which interrupts the manner in which nerve impulses are conducted. This results in problems with movement, eyesight, and sensory experiences.

While it appears that there is little question about Copaxone's effectiveness, how it works remains a bit of a mystery. In simple terms, Dr. Metz feels that the drug decreases the activation of harmful T-cells, while increasing anti-inflammatory cytokines "so it decreases bad and it increases good."

The drug is now being tested in people with progressive MS, which affects about 20% of those with MS.

Go To Page: 1

Articles in this Topic    Discussions in this Topic